tbuckley/cabot-search huggingface dataset:
Angiotensin AT1A receptors on leptin receptor–expressing cells control resting metabolism
Authors: Kristin E. Claflin, Jeremy A. Sandgren, Allyn M. Lambertz, Benjamin J. Weidemann, Nicole K. Littlejohn, Colin M.L. Burnett, Nicole A. Pearson, Donald A. Morgan, Katherine N. Gibson-Corley, Kamal Rahmouni, Justin L. Grobe
Journal: Journal of Clinical Investigation (2017)

Leptin contributes to the control of resting metabolic rate (RMR) and blood pressure (BP) through its actions in the arcuate nucleus (ARC). The renin-angiotensin system (RAS) and angiotensin AT1 receptors within the brain are also involved in the control of RMR and BP, but whether this regulation overlaps with leptin’s actions is unclear. Here, we have demonstrated the selective requirement of the AT1A receptor in leptin-mediated control of RMR. We observed that AT1A receptors colocalized with leptin receptors (LEPRs) in the ARC. Cellular coexpression of AT1A and LEPR was almost exclusive to the ARC and occurred primarily within neurons expressing agouti-related peptide (AgRP). Mice lacking the AT1A receptor specifically in LEPR-expressing cells failed to show an increase in RMR in response to a high-fat diet and deoxycorticosterone acetate–salt (DOCA-salt) treatments, but BP control remained intact. Accordingly, loss of RMR control was recapitulated in mice lacking AT1A in AgRP-expressing cells. We conclude that angiotensin activates divergent mechanisms to control BP and RMR and that the brain RAS functions as a major integrator for RMR control through its actions at leptin-sensitive AgRP cells of the ARC.
Chemotherapy-Based HLA Haploidentical Transplantation with Treg/Tcon Immunotherapy in Unfit/Elderly Leukemia Patients: Powerful Gvl Effect and Insights from Animal Models
Authors: Loredana Ruggeri, Alessandra Carotti, Franca Falzetti, Mauro Diianni, Antonio Pierini, Maria Speranza Massei, Lucia Amico, Sara Piccinelli, Elena Urbani, Massimo Fabrizio Martelli, Andrea Velardi
Journal: Blood (2016)
Mass Cytometry Reveals Heterogeneity in the Exhaustion Profile of T-Cells in Chronic Lymphocytic Leukemia and the CD4:CD8 Ratio May be a Reliable Predictor of CD8+ T Cell Compartment "Fitness"
Authors: Muharrem Muftuoglu, Li Li, Han Chen, Duncan Mak, Elif Gokdemir, Hila Shaim, Jared Burks, Rafet Basar, Nobuhiko Imahashi, Mayela Carolina Mendt, May Daher, David Marin, William G. Wierda, Nitin Jain, Michael J. Keating, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani
Journal: Blood (2016)
Secukinumab for the Treatment of Deficiency of Interleukin 36 Receptor Antagonist in an Adolescent
Authors: Vered Molho-Pessach, Rinad Alyan, Danielle Gordon, Hussein Jaradat, Abraham Zlotogorski
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Four questions help predict which patients do not need skin prick test, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

Asking people four simple questions can predict those who will have negative results in allergy tests and avoids unnecessary testing, a primary care study has shown.1

Symptoms associated with allergic disorders are common, but it is difficult to differentiate between those due to allergic (IgE-mediated) and non-allergic (non-IgE-mediated) conditions. As a result, many people undergo unnecessary allergy testing and then avoid potential allergens. It can also be difficult to interpret results because of …
Relief for Chronic Constipation
Authors: Rebecca Voelker
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopic management of large nonpedunculated colorectal polyps: selective treatment algorithms are needed
Authors: Halim Awadie, Alessandro Repici, Michael Bourke
Journal: Endoscopy (2017)

In this issue of Endoscopy, separate studies from two well-credentialed tertiary referral centers provide important information on colorectal endoscopic submucosal dissection (ESD). Together they tell us that in experienced tertiary centers, ESD for large (> 2 cm) nonpedunculated colorectal polyps (LNPCPs) is effective and safe, with recurrence being uncommon in long-term follow-up. Moreover, cure for those with submucosal invasive cancer (SMIC) is possible in a subgroup with low risk histological features (submucosal invasion < 1000 µm, no lympovascular invasion, well- or moderately well-differentiated tumor) if R0 excision has been achieved. However, despite the more than 10-year global experience with this technique in the colorectum, many questions about its true role in the treatment of LNPCPs remain unanswered.
OP20. THE IMPLICATIONS OF RISING CEREBRAL METASTASES INCIDENCE ON A LARGE-VOLUME NEURO-ONCOLOGY MULTI-DISCIPLINARY TEAM (MDT)
Authors: Mr Jignesh Tailor, Dr Sandip Panesar, Mr Richard Gullan, Mr Ranj Bhangoo, Prof Keyoumars Ashkan
Journal: Neuro-Oncology (2017)

BACKGROUND: The incidence of cerebral metastases (CM) encountered in clinical practice is increasing due to improved diagnostic imaging, global increase in primary cancer incidence and improved survival. The implications for neuro-oncology multi-disciplinary teams in tertiary referral centres are rarely reported. AIM: To review the current trends in CM referrals to our neuro-oncology MDT, including number of referrals, primary source demographics, MDT decisions and referral quality. METHOD: We conducted a 5-year systematic audit of all CM referrals to a large-volume multidisciplinary neuro-oncology team (MDT) and used the 2006 National Institute of Clinical Excellence (NICE) guidelines to benchmark. RESULTS: A total of 728 CM referrals were made from March 2009 through February 2014 (53.6% female and 46.4% male). We demonstrate a yearly increase in the total number of new CM referrals to the neuro-oncology MDT. The commonest primary sources were lung (31.9%), breast (19.9%), and colorectal cancers (5.4%). Despite increase in total referrals, the number of CM patients accepted by the MDT for specialist intervention (neurosurgery or stereotactic radiosurgery (SRS)) did not increase, whilst the number being advised for local management (palliation or whole brain radiotherapy) increased significantly. An increasing number of patients with multiple cerebral metastases were referred to the MDT over the 5-year period. We also found large proportion of CM referrals were incomplete with regards to inclusion of performance status and estimated prognosis, and a large number of patients had not been investigated for a primary source prior to referral (17.9%). CONCLUSION: The rising trend in CM referrals to neuro-oncology MDT is, to a large extent, driven by the referral of patients outside the original NICE guidelines such as those with multiple metastases.. The quality of referral information also falls short of NICE recommendations. Whilst the concept of MDT management may be applicable to all patients with metastatic brain disease, and complex neurosurgical interventions may be appropriate in a cohort of those with oligo-metastatic disease, the current set up of neuro-oncology MDTs, as directed by NICE guidelines, is not intended or designed to cater for these cases. The restructuring or diversification of neuro-oncology MDTs, supported with appropriate funding, will be required to address growing demands on these services. In the meantime, re-educating referrers on the NICE guidelines regarding the referral of patients with CM may go some way in balancing the current workload of the neuro-oncology MDTs.
Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia.
Authors: Leandro de Padua Silva, Jorge Cortes, Elias Jabbour, Sergio Giralt, Partow Kebriaei, Susan O’Brien, Amin Alousi, Muzaffar Qazilbash, Gabriela Rondon, Farhad Ravandi, Rachel Ribeiro, Chitra Hosing, Hagop Kantarjian, Richard Champlin, Marcos De Lima
Journal: Blood (2008)
A Single Cell Analysis of Immunoglobulin Genes in Chronic Lymphocytic Leukemia (CLL): Evidence of Intraclonal Diversification Associated with Progressive Somatic Mutations and Progressive Antigen Drive in Immunoglobulin Heavy and Light Chains.
Authors: Marc C. Levesque, Alicia D. Volkheimer, Bethany E. Beasley, Jon P. Gockerman, Joseph O. Moore, J. Brice Weinberg
Journal: Blood (2005)
LACE - an Effective Conditioning Regimen for Lymphoma Patients Undergoing Autologous Transplant- Analysis of Outcomes and Prognostic Factors
Authors: Deepan Rajamanickam, Anant Gokarn, Alok Gupta, Sachin Punatar, Ravi Thippeswamy, Bhausaheb Bagal, Libin Mathew, Sadhana Kannan, Venkatesh Rangarajan, Navin Khattry
Journal: Blood (2014)
Defining eligibility of FOLFIRINOX for first-line metastatic pancreatic adenocarcinoma (MPC) in the province of British Columbia: A population-based retrospective study.
Authors: Sharlene Gill, Maria Yi Ho, Hagen F. Kennecke, Daniel John Renouf, Winson Y. Cheung, Howard John Lim
Journal: Journal of Clinical Oncology (2012)

e14588 Background: FOLFIRINOX is a first line treatment option for patients with MPC and is associated with improved survival yet significantly more treatment-related toxicities than standard gemcitabine.. Our aim was to determine the proportion of patients with MPC who would be eligible for FOLFIRINOX therapy based upon the pivotal ACCORD study eligibility criteria. Methods: Patients with confirmed metastatic pancreatic cancer at the time of referral to the BC Cancer Agency between 2004-2007 were identified from the GI Outcomes Unit Database. Proportion of patients that met the ACCORD study eligibility criteria was determined by chart review. Criteria for FOLFIRINOX exclusion were assessed using descriptive statistics. Results: 100 consecutive patients with complete chart records and metastatic pancreatic cancer were identified. 52(52%) were male and the median age was 68. The most common sites of metastases were liver (63%) and peritoneum (22%). Only 26 patients fulfilled the ACCORD study eligibility criteria. The most common reasons for FOLIFIRINOX exclusion per ACCORD were poor ECOG score of 2 or greater (64%), age of 76y or greater (22%), elevated bilirubin (22%) and inadequate renal function (6%). Conclusions: Despite the proven survival benefit of FOLFIRINOX, only one-quarter of real-world patients with MPC would potentially be considered eligible for such combination chemotherapy.
Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center
Authors: Tracy E Wiczer, Lauren B Levine, Jessica Brumbaugh, Jessica Coggins, Qiuhong Zhao, Amy S. Ruppert, Anli McCoy, Kami J. Maddocks, Beth A Christian, Kerry A. Rogers, Leslie Andritsos, Samantha Jaglowski, Steven M Devine, Pierluigi Porcu, Jennifer A. Woyach, Jeffrey Jones, Michael R. Grever, John C. Byrd, Farrukh T. Awan
Journal: Blood (2016)
Anti-CD45 Pretargeted Radioimmunotherapy in a Nonhuman Primate Model.
Authors: Damian J. Green, John M. Pagel, Eneida R. Nemecek, Anastasia Pantelias, Yukang Lin, Aimee L. Kenoyer, Darrell R. Fisher, D.S. Wilbur, Donald K. Hamlin, Ajay K. Gopal, Oliver W. Press
Journal: Blood (2007)
Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival
Authors: Robert D. Rice, Craig H. Moskowitz, Tarun Kewalramani, Daniel O. Persky, Brian T. Rafferty, Jocelyn C. Maragulia, Andrew D. Zelenetz
Journal: Blood (2007)
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial
Authors: Pier Luigi Zinzani, Cinzia Pellegrini, Annalisa Chiappella, Alice Di Rocco, Flavia Salvi, Maria Giuseppina Cabras, Lisa Argnani, Vittorio Stefoni
Journal: Blood (2017)
Stem Cell Factor (SCF) Improves Thymopoiesis After Experimental Hematopoietic Stem Cell Transplantation In Both a Murine BMT Model and In “human Immune system” (HIS) Mice, Receiving a Human Stem Cell Graft.
Authors: Elwin J Rombouts, Evert-Jan Wils, Irene Van Mourik, Nicolas Legrand, Hergen Spits, Jan J. Cornelissen
Journal: Blood (2010)
Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.
Authors: Joon Seong Park, Dong Hwan Kim, Chul Won Choi, Seong Hyun Jeong, Jin-Hyuk Choi, Kihyun Kim, Seok Jin Kim, Chul Won Jung, Deok-Hwan Yang, Hugh Chul Kim, Jun Ho Jang
Journal: Blood (2009)
Molecular Aberrations of Chronic Neutrophilic Leukemia: The CSF3R and SETBP1 Mutations
Authors: Yajuan Cui, Bing Li, Robert Peter Gale, Qian Jiang, Zefeng Xu, Tiejun Qin, Peihong Zhang, Yue Zhang, Zhijian Xiao
Journal: Blood (2014)
Immune Dysfunctions of Cultured T Lymphocytes Are Due to a Preferential Expansion of CD4+CD25+ Suppressor Cells.
Authors: Mariana Mesel-Lemoine, Mustapha Cherai, Sabine Le Gouvello, Maude Guillot, Virginie Leclercq, David Klatzmann, Véronique Thomas-Vaslin, Francois M. Lemoine
Journal: Blood (2005)
Myocardial Infarct Size by CMR in Clinical Cardioprotection Studies
Authors: Heerajnarain Bulluck, Matthew Hammond-Haley, Shane Weinmann, Roberto Martinez-Macias, Derek J. Hausenloy
Journal: JACC. Cardiovascular imaging (2017)

The aim of this study was to review randomized controlled trials (RCTs) using cardiac magnetic resonance (CMR) to assess myocardial infarct (MI) size in reperfused patients with ST-segment elevation myocardial infarction (STEMI).There is limited guidance on the use of CMR in clinical cardioprotection RCTs in patients with STEMI treated by primary percutaneous coronary intervention.All RCTs in which CMR was used to quantify MI size in patients with STEMI treated with primary percutaneous coronary intervention were identified and reviewed.Sixty-two RCTs (10,570 patients, January 2006 to November 2016) were included. One-third did not report CMR vendor or scanner strength, the contrast agent and dose used, and the MI size quantification technique. Gadopentetate dimeglumine was most commonly used, followed by gadoterate meglumine and gadobutrol at 0.20 mmol/kg each, with late gadolinium enhancement acquired at 10 min; in most RCTs, MI size was quantified manually, followed by the 5 standard deviation threshold; dropout rates were 9% for acute CMR only and 16% for paired acute and follow-up scans. Weighted mean acute and chronic MI sizes (≤12 h, initial TIMI [Thrombolysis in Myocardial Infarction] flow grade 0 to 3) from the control arms were 21 ± 14% and 15 ± 11% of the left ventricle, respectively, and could be used for future sample-size calculations. Pre-selecting patients most likely to benefit from the cardioprotective therapy (≤6 h, initial TIMI flow grade 0 or 1) reduced sample size by one-third. Other suggested recommendations for standardizing CMR in future RCTs included gadobutrol at 0.15 mmol/kg with late gadolinium enhancement at 15 min, manual or 6-SD threshold for MI quantification, performing acute CMR at 3 to 5 days and follow-up CMR at 6 months, and adequate reporting of the acquisition and analysis of CMR.There is significant heterogeneity in RCT design using CMR in patients with STEMI. The authors provide recommendations for standardizing the assessment of MI size using CMR in future clinical cardioprotection RCTs.
Abstract S2-01: Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients
Authors: FJ Couch, C Hu, J Lilyquist, H Shimelis, M Akinhanmi, J Na, EC Polley, SN Hart, R McFarland, H LaDuca, R Huether, DE Goldgar, JS Dolinsky
Journal: Cancer Research (2017)

Abstract Clinical genetic testing panels are broadly used to gather information about cancer predisposition in individuals with personal and/or family history of breast cancer. However, the involvement of several of the genes on clinical testing panels in predisposition to breast cancer, such as MRE11A and RAD50, has recently come into question. In addition, accurate risk estimates for breast and other cancer are not well defined for the majority of genes on testing panels. We studied 60,000 women diagnosed with breast cancer who were tested for germline cancer predisposing mutations using hereditary cancer gene panels. Information on personal and family cancer history, age of diagnosis, and ethnicity of patients was obtained from test requisition forms. Greater than 90% met National Comprehensive Cancer Network HBOC testing criteria. To estimate gene-specific risks for breast cancer, case-control analyses were performed comparing the frequencies of pathogenic mutations from Caucasian cancer cases with frequencies from Caucasian, non-Finnish, non-TCGA controls from the Exome Aggregation Consortium (ExAC) database. Mutations were detected in 9% of breast cancer patients. Twelve genes displayed a significant association (p&amp;lt;0.05) with breast cancer. Nine of these genes, including ATM, RAD51D, NF1, and MSH6, were associated with moderate risk (RR&amp;gt;2.0) of breast cancer and three genes (BRCA1, BRCA2, PALB2) were associated with high risk (RR&amp;gt;5.0) of breast cancer. Cumulative age-dependent risk models were developed for each gene. This large clinical testing dataset of 60,000 women with breast cancer provides useful data for many predisposition genes previously lacking risk estimates, and should prove useful for clinical risk management of patients with inherited mutations in these genes. Citation Format: Couch FJ, Hu C, Lilyquist J, Shimelis H, Akinhanmi M, Na J, Polley EC, Hart SN, McFarland R, LaDuca H, Huether R, Goldgar DE, Dolinsky JS. Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr S2-01.
The Effect of Fresh Frozen Plasma On the Incidence of Venous Thromboembolism and Haemorrhages in Children with Acute Lymphoblastic Leukaemia
Authors: Charlotte CM Zuurbier, Eva Stokhuijzen, Cor van den Bos, Antoinette YN Schouten-van Meeteren, C Heleen Van Ommen
Journal: Blood (2012)
Haploidentical Stem Cell Transplantation (SCT) Using Flamsa Regimen As Salvage Chemotherapy
Authors: Meltem Kurt Yuksel, Ayla Gokmen, Muhit Ozcan, Onder Arslan, Osman Ilhan, Devrim Ozbek, Mevlude Kurdal Okcu, Ozlem Koktas
Journal: Blood (2014)
Correction
Journal: Cancer Research (2004)

In the article on breast vasculature in the November 1, 2004 issue of Cancer Research (1), Saraswati Sukumar should have been included in the requests for reprints note along with Stephen L. Madden.1. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, Saha S, Bardelli A, Jiang Y, St. Martin TB, Nacht M, Teicher BA, Klinger KW, Sukumar S, Madden SL. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004;64:7857–66.
LOW VERSUS HIGH ACETYLCHOLINE DOSE RESPONSE IN PATIENTS WITH VASOSPASTIC ANGINA
Authors: Sung Il Im, Seung-Woon Rha, Amro Elnagar, Byoung Geol Choi, Sunwon Kim, Jin Oh Na, Seongwoo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Hong-Seog Seo, Chang Gyu Park, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2012)
Are Tooth Decay Prevention Visits in Primary Care Before Age 2 Years Effective?
Authors: Peter M. Milgrom, Joana Cunha-Cruz
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal